A conserved dendritic-cell regulatory program limits antitumour immunity-Reference-Cited by-同舟云学术

A conserved dendritic-cell regulatory program limits antitumour immunity

Published:2020-03-25 Issue:7802 Volume:580 Page:257-262
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Maier Barbara,Leader Andrew M.,Chen Steven T.,Tung Navpreet,Chang Christie^ORCID,LeBerichel Jessica,Chudnovskiy Aleksey,Maskey Shrisha,Walker Laura,Finnigan John P.^ORCID,Kirkling Margaret E.^ORCID,Reizis Boris,Ghosh Sourav,D’Amore Natalie Roy,Bhardwaj Nina,Rothlin Carla V.,Wolf Andrea,Flores Raja,Marron Thomas,Rahman Adeeb H.,Kenigsberg Ephraim,Brown Brian D.,Merad Miriam

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41586-020-2134-y.pdf

Reference31 articles.

1. Sánchez-Paulete, A. R. et al. Intratumoral immunotherapy with XCL1 and sFlt3L encoded in recombinant Semliki Forest Virus-derived fosters dendritic cell-mediated T-cell cross-priming. Cancer Res. 78, 6643–6654 (2018).

2. Salmon, H. et al. Expansion and activation of CD103+ dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity 44, 924–938 (2016).

3. Broz, M. L. et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell 26, 638–652 (2014).

4. Lavin, Y. et al. Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses. Cell 169, 750–765 (2017).

5. Ginhoux, F. et al. The origin and development of nonlymphoid tissue CD103+ DCs. J. Exp. Med. 206, 3115–3130 (2009).

Cited by 558 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Powerful microscopy technologies decode spatially organized cellular networks that drive response to immunotherapy in humans;Current Opinion in Immunology;2024-12

2. Tertiary lymphoid structures as potential biomarkers for cancer prediction and prognosis;International Immunopharmacology;2024-10

3. Syndecan-1 inhibition promotes antitumor immune response and facilitates the efficacy of anti-PD1 checkpoint immunotherapy;Science Advances;2024-09-13

4. Neoadjuvant androgen deprivation therapy with or without Fc-enhanced non-fucosylated anti-CTLA-4 (BMS-986218) in high risk localized prostate cancer: a randomized phase 1 trial;2024-09-11

5. Phenotypic and spatial heterogeneity of CD8+ tumour infiltrating lymphocytes;Molecular Cancer;2024-09-09